QLC1401

· Qilu Pharmaceutical Co., Ltd.

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for QLC1401, covering 2025-09-15 to 2025-09-15. Get the full timeline:

Most recent: Clinical Trial Update: A Phase Ib/II Study of QLC1401 Combined With CDK4/6 or mTOR Inhibitors in ER+/HER2- Advanced Breast Cancer [Phase 1, Phase 2]

See pricing